scholarly journals Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors

2017 ◽  
Vol 22 (4) ◽  
pp. 377 ◽  
Author(s):  
Jennifer Wheler ◽  
David Mutch ◽  
Joanne Lager ◽  
Christelle Castell ◽  
Li Liu ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Dose Escalation Study

A Phase I Dose-Escalation Study of SR271425, an Intravenously Dosed Thioxanthone Analog, Administered Weekly in Patients With Refractory Solid Tumors

2009 ◽  
Vol 32 (1) ◽  
pp. 9-14 ◽  
Author(s):  
A Craig Lockhart ◽  
Emiliano Calvo ◽  
Anthony W. Tolcher ◽  
Eric K. Rowinsky ◽  
Gareth Shackleton ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Dose Escalation Study

A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

2012 ◽  
Vol 18 (9) ◽  
pp. 2658-2667 ◽  
Author(s):  
Klaus Mross ◽  
Annette Frost ◽  
Simone Steinbild ◽  
Susanne Hedbom ◽  
Martin Büchert ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study

scholarly journals Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

2009 ◽  
Vol 66 (4) ◽  
pp. 669-680 ◽  
Author(s):  
Francisco Robert ◽  
Alan Sandler ◽  
Joan H. Schiller ◽  
Glenn Liu ◽  
Karen Harper ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study

scholarly journals A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors

2014 ◽  
Vol 74 (5) ◽  
pp. 917-925 ◽  
Author(s):  
Carlos R. Becerra ◽  
Paul Conkling ◽  
Nicholas Vogelzang ◽  
Hilary Wu ◽  
Shengyan Hong ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study

scholarly journals Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors

2014 ◽  
Vol 20 (18) ◽  
pp. 4747-4757 ◽  
Author(s):  
Paul Haluska ◽  
Michael Menefee ◽  
Elizabeth R. Plimack ◽  
Jonathan Rosenberg ◽  
Donald Northfelt ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study
Sign in / Sign up

Export Citation Format

Share Document